Loading clinical trials...
Loading clinical trials...
This is a Feasibility/Phase II study for patients with a diagnosis of WHO Grade I - III Meningioma \& Hemangiopericytoma brain cancer to be given standard dose Proton radiotherapy. The study will be p...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Abramson Cancer Center at Penn Medicine
NCT05278208 · High Grade Glioma, Meningioma, and more
NCT06275919 · Meningioma, Malignant
NCT05940493 · Meningioma
NCT02523014 · Intracranial Meningioma, Recurrent Meningioma, and more
NCT06377371 · Meningioma
Abramson Cancer Center of the Unviersity of Pennsylvania
Philadelphia, Pennsylvania
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions